Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Methods in Molecular Medicine|March 5, 2011
Drug resistance : the clinical perspectiveD A Anthoney, S B Kaye
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|August 14, 2002
DNA: still a target worth aiming at? A review of new DNA-interactive agentsD A Anthoney, C J Twelves
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanomaD A Anthoney, I Bone, T R Evans
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 24, 2005
Intravenous irinotecan plus oral ciclosporinN S Vasudev, S Jagdev, D A Anthoney, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 1995
Colonic adenocarcinoma associated ectopic ACTH secretion: a case historyD A Anthoney, D J Dunlop, J M Connell, et al.
Annals of Clinical Biochemistry|April 26, 2007
Monitoring the treatment of carcinoid disease using blood serotonin and plasma 5-hydroxyindoleacetic acid: three case examplesK R Allen, T J Degg, D A Anthoney, et al.
Cancer Research|March 15, 1996
Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cellsD A Anthoney, A J McIlwrath, W M Gallagher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2004
Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resectionK Patel, D A Anthoney, A M Crellin, et al.
British Journal of Cancer|April 20, 2006
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinomaM E Burge, D Smith, C Topham, et al.
British Journal of Cancer|February 5, 2004
Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumoursD A Anthoney, M J McKean, J T Roberts, et al.
Pageof 2